Figure 3.
Kaplan-Meier survival curves for OS and CIR of patients with CEBPAsm comparing CEBPAsm in bZIP and CEBPAsm out-of bZIP. Analyses were performed for 54 of 59 patients with CEBPAsm AML who were followed up. Kaplan-Meier curves were stratified according to whether CEBPA mutation was “in” or “out-of” the bZIP domain: red, CEBPAmu in bZIP; blue, CEBPAmu out-of bZIP. (A) Kaplan-Meier curve of OS for all patients (A), Kaplan-Meier curve of CIR for all patients (B), Kaplan-Meier curve of OS for patients aged ≤70 years and with intermediate-risk karyotype (C), and Kaplan-Meier curve of CIR for patients aged ≤70 years and with intermediate-risk karyotype (D).

Kaplan-Meier survival curves for OS and CIR of patients with CEBPAsm comparing CEBPAsm in bZIP and CEBPAsm out-of bZIP. Analyses were performed for 54 of 59 patients with CEBPAsm AML who were followed up. Kaplan-Meier curves were stratified according to whether CEBPA mutation was “in” or “out-of” the bZIP domain: red, CEBPAmu in bZIP; blue, CEBPAmu out-of bZIP. (A) Kaplan-Meier curve of OS for all patients (A), Kaplan-Meier curve of CIR for all patients (B), Kaplan-Meier curve of OS for patients aged ≤70 years and with intermediate-risk karyotype (C), and Kaplan-Meier curve of CIR for patients aged ≤70 years and with intermediate-risk karyotype (D).

Close Modal

or Create an Account

Close Modal
Close Modal